AGP Picks
View all

Kalbitor market forecast points to faster growth in rare disease care

Nov. 5, 2026
Kalbitor market forecast points to faster growth in rare disease care
By AI, Created 18:00 UTC, Nov 05, 2026, AGP -

The Business Research Company says the Kalbitor market is set to expand through 2035 as hereditary angioedema diagnoses rise, specialty care broadens and reimbursement improves. North America led the market in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.

Why it matters: - Kalbitor is a targeted acute treatment for hereditary angioedema, a rare disorder that can cause sudden swelling in the limbs, gut and airways. - Rising diagnosis rates and broader access to specialty care could expand demand for emergency therapies in a rare disease market where fast symptom relief is critical. - The market outlook also signals where drugmakers, specialty centers and payers may focus resources as orphan-drug coverage improves.

What happened: - The Business Research Company published its Kalbitor Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 5, 2026. - The report says the Kalbitor market grew steadily in the historical period because of limited treatment options for hereditary angioedema, high complication rates from untreated acute episodes, early approvals of biologic treatments, specialist prescribing patterns and hospital-based emergency care. - The report projects growth from 2026 to 2030 on the back of more genetic testing, more targeted biologic therapies, greater awareness of rare angioedema conditions, more specialty immunology centers and better reimbursement for orphan drugs. - The company identified North America as the leading regional market in 2025 and Asia-Pacific as the fastest-growing region in the forecast period.

The details: - Kalbitor, or ecallantide, is a recombinant protein that inhibits plasma kallikrein. - Plasma kallikrein helps produce bradykinin, which drives inflammation and swelling. - Kalbitor is mainly used to treat acute attacks of hereditary angioedema. - The report highlights growing use of kallikrein inhibitors, stronger management of acute HAE attacks, more emergency therapies for rare diseases, faster symptom relief and expanded specialty care for angioedema patients. - A nationwide Belgian study published in Frontiers in Allergy in May 2023 found a minimum HAE prevalence of 1.56 per 100,000 people and 179 patients registered at specialized Belgian centers. - The Population Reference Bureau said in January 2024 that the U.S. population age 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, lifting the share of the population from 17% to 23%. - The U.K. Office for National Statistics said in May 2024 that total healthcare spending rose 5.6% in nominal terms from 2022 to 2023, up from 0.9% the year before. - The report’s regional coverage includes Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - More information is available in the full report and the free sample.

Between the lines: - The report frames Kalbitor’s growth as a function of better diagnosis, not just higher disease burden. - Specialty-center expansion and reimbursement policy changes suggest the market is becoming less dependent on emergency-only treatment pathways. - Aging populations and higher healthcare spending may widen access to rare-disease therapies even as the patient base remains small.

What's next: - The report expects genetic testing, specialty immunology access and orphan-drug reimbursement to stay central to market growth through 2030. - Asia-Pacific is positioned for the strongest regional growth as awareness and healthcare access improve. - Demand should continue to center on acute HAE management and rapid symptom control, which keeps emergency-use therapies relevant in the treatment mix.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Belgium Health Review

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Belgium Health Review

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.